News
albeit only for insomnia associated with depression. Japan's Taisho Pharma meanwhile has vornorexant in phase 2 trials as an insomnia therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback